- Champignon Brands Continues to Bolster its Impressive Team with the Company Appointing Pat McCutcheon to its Board of Directors
- As the Founder, CEO and Chairman of MediPharm Labs, McCutcheon was Instrumental in Creating One of the Cannabis Sector’s Only Profitable Pot Stocks
- McCutcheon’s Capital Raising Expertise, Leadership Skills and Business Acumen Will Be Valuable Assets for Champignon as it Begins to Accelerate its North American Expansion of New Psychedelic Clinics
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced on Wednesday the appointment of Pat McCutcheon to the company’s board of directors effective immediately. Pat McCutcheon is the Founder and current Chairman and CEO of MediPharm Labs (TSX: LABS) (OTCQX: MEDIF) (FRA: MLZ).
After identifying an essential and overlooked segment of the marijuana market, McCutcheon created the cannabis industry’s first extraction pure-play in MediPharm Labs. Under McCutcheon’s leadership over the past three years, MediPharm has become a top-five revenue-generating company within the Canadian cannabis industry. Even more impressive, MediPharm is one of the few profitable cannabis companies.
“2019 was a transformational year for MediPharm Labs. We were one of only a very few cannabis companies to successfully execute on its strategy and be profitable,” said McCutcheon in MediPharm’s most recent earnings release.
“We are tremendously pleased to have Pat join the Champignon Board. His extensive experience in commercial development across the pharmaceutical industry combined with direct experience operating and scaling highly profitable businesses further strengthens our board with expertise that will accelerate the expansion of our clinical footprint via the establishment of net new clinical entities, as well as industry partnerships for ketamine, psilocybin and MDMA,” said Champignon CEO Gareth Birdsall.
McCutcheon holds an honours bachelor of science degree in biology from the University of Western Ontario and, before founding MediPharm, held senior roles with various large pharmaceutical companies such as Astra Zeneca, Sanofi and Jansen Pharmaceuticals (Johnson & Johnson).
“I am excited to join the Board of Directors of Champignon given its leadership position with the only licensed operating ketamine clinic and integrated research centre of its kind in Canada. I look forward to working with the board and the company’s management team to advance Champignon’s clinical development and expansion program in the US and Canada. I also look forward to assisting the company with its plan to evaluate other assets and new partnerships that will expand its pipeline in the rapidly emerging ketamine and psilocybin for mental health industry that has demonstrated strong potential in a short period of time,” stated McCutcheon.
In other related news, Champignon reported the appointment of Matthew Fish, JD, as the company’s new President and Secretary. Mr. Fish will help guide Champignon as the company ramps up its North American roll-out of new psychedelic clinics.
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.